20 articles
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
New research identifies FTL1 protein as key driver of brain aging. Reducing it restored memory and neural connections in mice.
Blocking the protein PTP1B boosted memory and cleared brain plaque in mice, with potential links to diabetes and obesity treatment.
Clinical trial shows solriamfetol significantly improves alertness and performance in workers who start before sunrise.
Declining Menin in the hypothalamus drives inflammation and aging. Restoring it reversed decline; D-serine amino acid improved cognition in mice.
The SenNet atlas reveals where aging cells accumulate in human tissues, opening new doors for senolytic therapies and healthspan extension.
New gene therapy zorevunersen dramatically reduced seizures in children with severe Dravet syndrome epilepsy while improving quality of life.
Researchers created modified psilocin that maintains antidepressant effects while dramatically reducing psychedelic side effects in mice.
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
Researchers discover toxic protein pair that kills brain cells in Alzheimer's and develop compound to block it in mice.
Major study identifies three existing drugs that could be repurposed to fight Alzheimer's disease, offering faster path to treatment.
A small trial found tocilizumab, an anti-inflammatory drug, cut depression remission rates better than SSRIs by targeting IL-6, not brain chemistry.
Researchers turned ordinary brain cells into plaque-clearing machines, reducing Alzheimer's amyloid by half in mice with one treatment.
Researchers finally discovered how lecanemab clears brain plaques by activating immune cells through a specific antibody fragment.
A Rutgers study finds GLP-1 users show dramatically weaker links between impulsivity, alcohol use, and violent behavior.
Raising Sox9 levels in aging astrocytes reduced amyloid plaque buildup and protected memory in mouse models with existing Alzheimer's symptoms.
Researchers finally discovered lecanemab activates brain immune cells through a specific antibody fragment to clear toxic plaques.
A home-based walking and resistance program improved attention and reduced observable cognitive decline in chemotherapy patients over 6 weeks.
A molecule called OLE restores microglia's protective function, reducing amyloid plaques and improving memory in animal models.
